Literature DB >> 19632736

Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer.

Miep A van der Drift1, Bernard E A Hol, Corné H W Klaassen, Clemens F M Prinsen, Yvonne A W G van Aarssen, Rogier Donders, Jos W J van der Stappen, P N Richard Dekhuijzen, Henricus F M van der Heijden, Frederik B J M Thunnissen.   

Abstract

INTRODUCTION: Circulating plasma DNA is present in a considerably higher concentration in lung cancer patients than in controls. Conflicting data are reported about circulating DNA as a prognostic factor. The aim of this study was to prospectively analyse the relationship of circulating plasma DNA with overall survival (OS) of previously untreated non-small cell lung cancer (NSCLC) patients.
METHODS: 46 untreated NSCLC patients and 21 controls with a follow-up time of 6.5 years were analyzed. Quantification of baseline circulating plasma DNA was performed by a real-time quantitative polymerase chain reaction (qPCR) targeting the human beta-globin gene. Survival analysis was performed using the Kaplan-Meier method and compared with a Cox-regression analysis.
RESULTS: The median DNA concentration of the patients who died (87%) was significantly higher compared to the patients that survived at the end of follow-up (55ng/ml versus 23ng/ml, p=0.02). In patients with higher DNA concentration overall survival was significantly worse. In this study no relation of DNA concentration with tumour characteristics, age, gender or pulmonary inflammatory conditions was found.
CONCLUSION: In this study a high circulating plasma DNA concentration at time of diagnosis in NSCLC patients was a prognostic factor for poorer survival. Circulating DNA may be used as a non-invasive biomarker to refine the prognostic profile in NSCLC patients. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632736     DOI: 10.1016/j.lungcan.2009.06.021

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  26 in total

Review 1.  Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.

Authors:  Paola Ulivi; Rosella Silvestrini
Journal:  Cell Oncol (Dordr)       Date:  2013-11-01       Impact factor: 6.730

2.  A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.

Authors:  B T Li; A Drilon; M L Johnson; M Hsu; C S Sima; C McGinn; H Sugita; M G Kris; C G Azzoli
Journal:  Ann Oncol       Date:  2015-10-20       Impact factor: 32.976

Review 3.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

Review 4.  Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.

Authors:  Giulia De Maio; Claudia Rengucci; Wainer Zoli; Daniele Calistri
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

5.  Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma.

Authors:  Avery Sonnenberg; Jennifer Y Marciniak; Elaine A Skowronski; Sareh Manouchehri; Laura Rassenti; Emanuela M Ghia; George F Widhopf; Thomas J Kipps; Michael J Heller
Journal:  Electrophoresis       Date:  2014-05-14       Impact factor: 3.535

6.  Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood.

Authors:  Avery Sonnenberg; Jennifer Y Marciniak; Laura Rassenti; Emanuela M Ghia; Elaine A Skowronski; Sareh Manouchehri; James McCanna; George F Widhopf; Thomas J Kipps; Michael J Heller
Journal:  Clin Chem       Date:  2013-11-22       Impact factor: 8.327

7.  Circulating tumour markers can define patients with normal colons, benign polyps, and cancers.

Authors:  R Mead; M Duku; P Bhandari; I A Cree
Journal:  Br J Cancer       Date:  2011-06-28       Impact factor: 7.640

8.  A modified extraction method of circulating free DNA for epidermal growth factor receptor mutation analysis.

Authors:  Haihua Yuan; Zhong-Zheng Zhu; Yachao Lu; Feng Liu; Wenying Zhang; Gang Huang; Guanshan Zhu; Bin Jiang
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

9.  Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients.

Authors:  Raquel Catarino; Ana Coelho; António Araújo; Mónica Gomes; Augusto Nogueira; Carlos Lopes; Rui Medeiros
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

10.  Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy.

Authors:  Feng Zhu; Jing Ma; Dongdong Ru; Ningning Wu; Yunhua Zhang; Huiyuan Li; Xiaoli Liu; Jianfeng Li; Huiling Zhang; Yue Xu; Jiangman Zhao; Hui Tang; Yusheng Wang; Weihua Fu
Journal:  J Oncol       Date:  2021-05-26       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.